MultiMetaVerse (MMVVF) 20-F 28 Apr 23 2022 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2022 shares
Document Information Line Items
Entity Registrant Name	MultiMetaVerse Holdings Ltd
Trading Symbol	MMV
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	2,284,542
Amendment Flag	false
Entity Central Index Key	0001874074
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-41587
Entity Incorporation, State or Country Code	D8
Entity Address, Address Line One	Building D3, No. 718
Entity Address, Address Line Two	Lingshi Road
Entity Address, City or Town	Jingan District Shanghai
Entity Address, Country	CN
Entity Address, Postal Zip Code	200072
Contact Personnel Name	Mr. Yiran Xu
Title of 12(b) Security	Class A ordinary shares
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Accounting Standard	U.S. GAAP
Auditor Firm ID	688
Auditor Name	Marcum llp
Auditor Location	Houston, TX
Business Contact
Document Information Line Items
Entity Address, Address Line One	Building D3, No. 718
Entity Address, Address Line Two	Lingshi Road
Entity Address, City or Town	Jingan District Shanghai
Entity Address, Country	CN
Entity Address, Postal Zip Code	200072
Contact Personnel Name	Mr. Yiran Xu
City Area Code	+86 21
Local Phone Number	61853907

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Assets
Cash	$ 2,222,795	$ 336,852
Prepaid expenses and other current assets	91,982	49,253
Total current assets	2,314,777	386,105
Marketable securities held in Trust Account	23,632,158	58,078,580
Total Assets	25,946,935	58,464,685
Liabilities, Shares Subject to Possible Redemption and Shareholders’ Deficit
Accrued offering costs and expenses	2,047,911	559,478
Due to related parties		58,413
Advances from PIPE investors	2,000,000
Promissory note – Legacy MMV	2,684,975
Total current liabilities	6,732,886	617,891
Warrant liability	16,375	52,151
Deferred underwriting fee	2,012,500	2,012,500
Total liabilities	8,761,761	2,682,542
Commitments and Contingencies (Note 8)
Class A ordinary shares subject to possible redemption, 2,241,006 and 5,750,000 shares at $10.55 and $10.10 redemption value as of December 31, 2022 and 2021, respectively	23,632,158	58,078,580
Shareholders’ Deficit:
Preference shares, no par value; 1,000,000 shares authorized; none issued and outstanding
Class A ordinary shares, no par value; 100,000,000 shares authorized; 350,000 issued and outstanding (excluding 2,241,006 and 5,750,000 subject to possible redemption as of December 31, 2022 and 2021, respectively)	2,925,000	2,925,000
Class B ordinary shares, no par value; 10,000,000 shares authorized; 1,437,500 shares issued and outstanding	25,001	25,001
Accumulated deficit	(9,396,985)	(5,246,438)
Total shareholders’ deficit	(6,446,984)	(2,296,437)
Total Liabilities, Shares Subject to Possible Redemption and Shareholders’ Deficit	$ 25,946,935	$ 58,464,685

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Preference shares par value (in Dollars per share)
Preference shares authorized	1,000,000	1,000,000
Preference shares issued
Preference shares outstanding
Class A Ordinary Shares
Ordinary shares subject to possible redemption	2,241,006	5,750,000
Ordinary shares redemption value (in Dollars per share)	$ 10.55	$ 10.1
Ordinary shares par value (in Dollars per share)
Ordinary shares authorized	100,000,000	100,000,000
Ordinary shares issued	350,000	350,000
Ordinary shares outstanding	350,000	350,000
Class B Ordinary Shares
Ordinary shares par value (in Dollars per share)
Ordinary shares authorized	10,000,000	10,000,000
Ordinary shares issued	1,437,500	1,437,500
Ordinary shares outstanding	1,437,500	1,437,500

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Formation and operating costs	$ 2,812,222	$ 960,518
Loss from operations	(2,812,222)	(960,518)
Other income:
Change in fair value of warrant liability	35,776	84,820
Trust interest income	522,672	3,580
Total other income	558,448	88,400
Net loss	$ (2,253,774)	$ (872,118)
Class A Ordinary Shares
Other income:
Basic and diluted weighted average shares outstanding (in Shares)	4,836,700	4,229,692
Basic and diluted net loss per (in Dollars per share)	$ (0.34)	$ (0.15)
Class B Ordinary Shares
Other income:
Basic and diluted weighted average shares outstanding (in Shares)	1,787,500	1,674,958
Basic and diluted net loss per (in Dollars per share)	$ (0.34)	$ (0.15)

Statements of Operations (Paren

Statements of Operations (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Class A Ordinary Shares
Basic and diluted weighted average shares outstanding	4,836,700	4,229,692
Basic and diluted net loss per	$ (0.34)	$ (0.15)
Class B Ordinary Shares
Basic and diluted weighted average shares outstanding	1,787,500	1,674,958
Basic and diluted net loss per	$ (0.34)	$ (0.15)

Statements of Changes in Shareh

Statements of Changes in Shareholders’ Deficit - USD ($)	Class A Ordinary Shares	Class B Ordinary Shares	Accumulated Deficit	Total
Balance at Jan. 07, 2021
Balance as of (in Shares) at Jan. 07, 2021
Issuance of Founder shares		$ 25,001		25,001
Issuance of Founder shares (in Shares)		1,437,500
Sale of 270,000 Private Placement Units on April 12, 2021	$ 2,700,000			$ 2,700,000
Sale of 270,000 Private Placement Units on April 12, 2021 (in Shares)	270,000			270,000
Sale of 22,500 Private Placement Units on April 15, 2021 through over-allotment	$ 225,000			$ 225,000
Sale of 22,500 Private Placement Units on April 15, 2021 through over-allotment (in Shares)	22,500			22,500
Issuance of representative shares			401,711	$ 401,711
Issuance of representative shares (in Shares)	50,000
Issuance of representative shares through over-allotment			60,257	60,257
Issuance of representative shares through over-allotment (in Shares)	7,500
Accretion of carrying value to redemption value			(4,257,708)	(4,257,708)
Additional amount in deposited into trust			(575,000)	(575,000)
Net loss			(872,118)	(872,118)
Accretion of interest income			(3,580)	(3,580)
Balance at Dec. 31, 2021	$ 2,925,000	$ 25,001	(5,246,438)	(2,296,437)
Balance (in Shares) at Dec. 31, 2021	350,000	1,437,500
Accretion of carrying value to redemption value				(4,257,708)
Remeasurement of Class A ordinary shares subject to possible redemption			(522,672)	(522,672)
Additional amount in deposited into trust			(1,374,101)	(1,374,101)
Net loss			(2,253,774)	(2,253,774)
Balance at Dec. 31, 2022	$ 2,925,000	$ 25,001	$ (9,396,985)	$ (6,446,984)
Balance (in Shares) at Dec. 31, 2022	350,000	1,437,500

Statements of Changes in Shar_2

Statements of Changes in Shareholders’ Deficit (Parentheticals)	12 Months Ended
	Dec. 31, 2021 shares
Statement of Stockholders' Equity [Abstract]
Sale of private placement units	270,000
Sale of private placement units through over-allotment	22,500

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (2,253,774)	$ (872,118)
Adjustments to reconcile net loss to net cash used in operating activities:
Formation costs paid by Sponsor		3,725
Interest earned on cash and marketable securities held in Trust Account	(522,672)	(3,580)
Change in fair value of warrant liability	(35,776)	(84,820)
Changes in current assets and liabilities:
Prepaid assets	(42,729)	103,747
Due to Related Party	(58,413)	58,413
Accrued expenses	1,488,433	559,478
Net cash used in operating activities	(1,424,931)	(235,155)
Cash flows from investing activities:
Amount deposited into trust	(1,374,101)	(58,075,000)
Disposal of investment held in Trust Account	36,343,195
Net cash provided by (used in) investing activities	34,969,094	(58,075,000)
Cash flows from financing activities:
Proceeds from loan from related party	2,684,975
Proceeds from initial public offering, net of costs		56,350,000
Proceeds from PIPE investment	2,000,000
Proceeds from private placement		2,925,000
Payment of advance from related party		(110,243)
Payment of promissory note from related party		(200,000)
Payment of deferred offering costs		(317,750)
Redemption of class A ordinary shares	(36,343,195)
Net cash (used in) provided by financing activities	(31,658,220)	58,647,007
Net change in cash	1,885,943	336,852
Cash, beginning of the period	336,852
Cash, end of the period	2,222,795	336,852
Supplemental disclosure of non-cash investing and financing activities:
Offering costs paid by Sponsor in exchange for issuance of ordinary shares		25,001
Offering costs paid by Sponsor under promissory note		153,518
Deferred underwriting discount		2,012,500
Initial classification of private warrants		136,971
Remeasurement of Class A ordinary shares subject to possible redemption, including additional amounts deposited into trust	$ 1,896,773

Organization, Business Operatio

Organization, Business Operation, Liquidation and Business Combination	12 Months Ended
	Dec. 31, 2022
Organization, Business Operation, Liquidation and Business Combination [Abstract]
Organization, Business Operation, Liquidation and Business Combination	Note 1 — Organization, Business Operation, Liquidation and Business Combination MultiMetaVerse Holdings Limited (formally known as Model Performance Acquisition Corp., now the “Company”) was incorporated as a British Virgin Islands business company on January 8, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). As of December 31, 2022, the Company had not commenced any operations. All activity for the period from January 8, 2021 (inception) through December 31, 2022 relates to the Company’s formation and the initial public offering (“IPO”), which is described below, and subsequent to the IPO, searching for a Business Combination target and the negotiation of the Business Combination Agreement as described below. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is First Euro Investments Limited, a British Virgin Islands company (the “Sponsor”). The registration statement for the Company’s IPO was declared effective on April 7, 2021 (the “Effective Date”). On April 12, 2021, the Company consummated the IPO of 5,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “public share”), at $10.00 per Unit, generating gross proceeds of $50,000,000, which is discussed in Note 3. Simultaneously with the closing of the IPO, the Company consummated the sale of 270,000 units (the “Private Placement”), at a price of $10.00 per Private Unit, which is discussed in Note 4. On April 15, 2021, the underwriters exercised the over-allotment option in full and purchased an additional 750,000 Units (the “Over-Allotment Units”), generating gross proceeds of $7,500,000. In connection with the closing of the purchase of the Over-Allotment Units, the Company sold an additional 22,500 Private Placement Units, generating gross proceeds of $225,000. Transaction costs of the IPO and the exercise of over-allotment option, amounted to $4,120,737 consisting of $1,150,000 of underwriting fee, $2,012,500 of deferred underwriting fee, $496,269 of other offering costs, and $461,968 of fair value of 57,500 representative’s ordinary shares. Following the closing of the IPO and the exercise of over-allotment option, $58,075,000 ($10.10 per Unit) from the net offering proceeds of the sale of the Units in the IPO, the sale of the Private Placement and the exercise of over-allotment option was placed in a trust account (the “Trust Account”) and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 180 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. On March 29, 2022, June 29, 2022 and September 29, 2022, the Company deposited into the Trust Account for an aggregate of $1,374,101 (representing $0.30 per Class A ordinary share) to extend the Combination Period from April 12, 2022 to January 12, 2023 (three three-months extensions). On September 29, 2022, $36,343,195 was paid from the Trust Account to MPAC public shareholders for redemption of 3,508,994 Class A ordinary shares. The remaining proceeds from the IPO and the sale of the Private Placement Units after redemption were released from the Trust Account until the completion of the initial Business Combination on January 4, 2023. Business Combination On January 4, 2023, the Company consummated the Business Combination pursuant to the merger agreement, entered into on August 6, 2021 (as amended on January 6 and September 29, 2022, the “Merger Agreement”), between the Company and MultiMetaVerse Inc., a Cayman Islands exempted company (“Legacy MMV”). Pursuant to the Merger Agreement, the Business Combination has been effected in two steps: (i) subject to the approval and adoption of the Merger Agreement by the shareholders of the Company, the Company reincorporated to British Virgin Islands by merging with and into Model Performance Mini Corp., a British Virgin Islands business company (“PubCo”, renamed to MultiMetaVerse Holdings Limited, “MMV”), with PubCo remaining as the surviving publicly traded entity (the “Reincorporation Merger”); and (ii) Model Performance Mini Sub Corp., a Cayman Islands exempted company and wholly-owned subsidiary of PubCo (“Merger Sub”), was merged with and into Legacy MMV resulting in Legacy MMV being a wholly-owned subsidiary of PubCo (the “Acquisition Merger”). The Merger Agreement is by and among the Company, PubCo, Merger Sub, Legacy MMV and certain shareholders of Legacy MMV (“Principal Shareholders”). The aggregate consideration for the Acquisition Merger is $300,000,000, payable in the form of 30,000,000 newly issued MMV ordinary shares valued at $10.00 per share. Immediately prior to the consummation of the Business Combination, all outstanding Units of the Company separated into their individual components of the Company’s Class A ordinary shares, public warrants and rights ceased separate existence and trading. Upon the consummation of the Business Combination, the Company’s Class B ordinary shares automatically converted into its Class A ordinary shares, and the current equity holdings of the the Company’s shareholders were exchanged as follows: ● Each Class A ordinary share issued and outstanding immediately prior to the effective time of the Reincorporation Merger (other than any redeemed shares) was automatically cancelled and ceased to exist and, for each Class A ordinary share, MMV shall issue to each of the Company’s shareholders (other than the shareholders who exercised their redemption rights in connection with the Business Combination or the Charter Amendment Proposal) one validly issued MMV Class A ordinary share; ● Each whole warrants issued and outstanding immediately prior to effective time of the Reincorporation Merger was converted into a warrant to purchase one MMV Class A ordinary share (each, a “MMV Warrant”) (or equivalent portion thereof). The MMV Warrants will have substantially the same terms and conditions as set forth in the Company’s warrants; and ● The holders of Rights issued and outstanding immediately prior to the effective time of the Reincorporation Merger received one-tenth (1/10) of one MMV Class A ordinary share in exchange for the cancellation of each Right; provided, however, that each holder entitled to receive a fraction of a MMV Class A ordinary share shall receive, in lieu of such fractional share, one MMV Class A ordinary share rounding up to the nearest whole MMV Class A ordinary share. On November 3, 2022, the Company and PubCo entered into a subscription agreement (the “Prominence Agreement”) with Prominence Investment Management Ltd. (“Prominence”), pursuant to which the Company and PubCo have agreed to issue and sell to Prominence an aggregate of 1,200,000 Class A ordinary shares, for an aggregate purchase price of $12,000,000 at $10.00 per share. As of December 31, 2022, the Company received $2 million of the PIPE financing. On January 30, 2023, MMV received another tranche of PIPE investment amounted to $2.5 million. After a series of negotiations, MMV and Prominence agreed to waive their remaining rights and obligations under the Prominence Agreement. Liquidity and Capital Resources As of December 31, 2022, the Company had $2,222,795 in cash (including $2 million from PIPE investment) and working capital deficiency of $4,418,109. The Company’s liquidity needs prior to the consummation of the IPO were satisfied through the proceeds of $200,000 under the Note (Note 6). Subsequent from the consummation of the IPO, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the IPO, the Private Placement held outside of the Trust Account and the Loan from Legacy MMV as described in Note 7. On January 10, 2022, March 21, 2022, June 21, 2022, June 29, 2022 and September 30 2022, the Company received loans for an aggregate of $2,684,975, from Legacy MMV. On January 4, 2023, the Company consummated the Business Combination pursuant to the terms of the Merger Agreement with Legacy MMV and became a wholly owned subsidiary of MMV. Following the Business Combination, the Company became part of MMV, and all its assets and liabilities became assets and liabilities of MMV; the Company has had no operations on its own at all and wouldn’t incur any additional expenses and liabilities for its business prior to the Business Combination. The Company’s ability to meet all of its obligations as of December 31, 2022 has been testified by the subsequent settlement by the Company itself or by MMV. As of the date that the financial statements were issued, the majority of the Company’s liabilities owed to third parties as of December 31, 2022 have been settled.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements are presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Emerging Growth Company The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, ( the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, Section 102(b)(1) of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of these financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents As of December 31, 2022 and 2021, the Company had $2,222,795 and $336,852 in cash. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash and cash equivalents. The Company did not have any cash equivalents as of December 31, 2022 and 2021. Marketable Securities Held in Trust Account At December 31, 2022 the assets held in the Trust Account were released to a Trust Operating Account, which was subsequently distributed on and after the Business Combination consummated on January 4, 2023. At December 31, 2021 the assets held in the Trust Account were held in institutional money market mutual funds and cash. The Company’s investments held in the Trust Account are classified as trading securities. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit. As of December 31, 2022 and 2021, the Company has not experienced losses on these accounts. Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, on December 31, 2022 and 2021, 2,241,006 and 5,750,000 shares of Class A ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders’ deficit section of the Company’s balance sheets. All of the 5,750,000 Class A ordinary share sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary share subject to redemption to be classified outside of permanent equity. The Class A ordinary share is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary share resulted in charges against additional paid-in capital and accumulated deficit. As of December 31, 2022 and 2021, the amount for Class A ordinary shares subject to possible redemption reflected in the balance sheets are reconciled in the following table: December 31, December 31, 2022 2021 Gross proceeds from IPO $ 57,500,000 $ 57,500,000 Less: Proceeds allocated to Warrants (136,971 ) (136,971 ) Ordinary share issuance costs (4,120,737 ) (4,120,737 ) Plus: Accretion of carrying value to redemption value 4,257,708 4,257,708 Additional amount deposited into trust 1,949,101 575,000 Remeasurement of Class A ordinary shares subject to possible redemption 526,252 3,580 Less: Class A ordinary shares redeemed on September 29, 2022 (36,343,195 ) — Contingently redeemable ordinary shares $ 23,632,158 $ 58,078,580 On March 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from April 12, 2022 to July 12, 2022. On June 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from July 12, 2022 to October 12, 2022. On September 29, 2022, $36,343,195 was paid from the Trust Account to MPAC public shareholders for redemption of 3,508,994 Class A ordinary shares, and $224,101 was deposited into the trust account by the Company, to extend the Combination Period from October 12, 2022 to January 12, 2023. Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A – “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the IPO and were charged to shareholders’ deficit upon the completion of the IPO, while the offering costs attributable to private placement warrants are immaterial and not recorded. Accordingly, as of December 31, 2022, offering costs in the aggregate of $4,120,737 have been charged to shareholders’ deficit (consisting of $1,150,000 of underwriting fee, $2,012,500 of deferred underwriting fee, and $496,269 of other offering costs, and $461,968 of fair value of 57,500 representative’s ordinary shares). Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature. Income Taxes ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the British Virgin Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the British Virgin Islands. In accordance with British Virgin Islands federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Warrant Liability The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. Derivative instruments are recorded at fair value on the grant date and re- valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. Financial Accounting Standards Board (“FASB”) ASC 470-20, Debt with Conversion and Other Options addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate IPO proceeds from the Units between Class A ordinary shares and warrants, using the residual method by allocating IPO proceeds first to fair value of the warrants and then the Class A ordinary shares. The Company accounts for the private placement warrants as warrant liabilities due to certain features contained in the warrant agreements that give rise to liability treatment. The public warrants are treated as equity as they do not meet the definition of a warrant liability. Net Loss Per Share The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 3,021,250 potential common shares for outstanding warrants to purchase the Company’s stock were excluded from diluted earnings per share for the year ended December 31, 2022 and for the period from January 8, 2021 (inception) through December 31, 2021, because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net loss per share for each class of ordinary shares: For the Period from For the Year Ended January 8, 2021 (Inception) to December 31, 2022 December 31, 2021 Class B and Class B and Redeemable Non-redeemable Redeemable Non-redeemable Class A Class B Class A Class B Numerator: Allocation of net loss (1,645,607 ) (608,167 ) (624,726 ) (247,392 ) Denominator: Weighted-average shares outstanding 4,836,700 1,787,500 4,229,692 1,674,958 Basic and diluted net loss per share (0.34 ) (0.34 ) (0.15 ) (0.15 ) Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 for the Company and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Initial Public Offering

Initial Public Offering	12 Months Ended
	Dec. 31, 2022
Initial Public Offering Disclosure Abstract
Initial Public Offering	Note 3 — Initial Public Offering Pursuant to the IPO, the Company sold 5,000,000 Units, (at a price of $10.00 per Unit. Each Unit consists of one Class A ordinary share, one-half of one redeemable warrant and one right. Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. Each right entitles the holder to receive one-tenth (1/10) of one Class A ordinary share upon consummation of the initial Business Combination. On April 15, 2021, the underwriter fully exercised their over-allotment option with respect to the 750,000 option units resulting in gross proceeds of $7,500,000.

Private Placement

Private Placement	12 Months Ended
	Dec. 31, 2022
Private Placement [Abstract]
Private Placement	Note 4 — Private Placement Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 270,000 Private Placement Units at a price of $10.00 per unit ($2,700,000 in the aggregate). Each Private Placement Unit is identical to the Units sold in the IPO, except as described below. There are no redemption rights or liquidating distributions from the Trust Account with respect to the founder shares, private placement shares, private placement warrants or private placement rights. The warrants and rights will expire worthless if the Company does not consummate a Business Combination within the allotted 12-month period (or up to 18 months from the completion of the IPO if the Company extends the period of time to consummate a Business Combination by the full amount of time). A portion of the purchase price of the Private Placement Units was added to the proceeds from this offering to be held in the Trust Account. Simultaneously with the full exercise of over-allotment option, the Sponsor purchased an aggregate of 22,500 Private Placement Units resulting in gross proceeds of $225,000.

Fair Value of Warrant Liabiliti

Fair Value of Warrant Liabilities	12 Months Ended
	Dec. 31, 2022
Fair Value of Warrant Liabilities Disclosure [Abstract]
Fair Value of Warrant Liabilities	Note 5 — Fair Value of Warrant Liabilities Fair value is defined as the price which would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities. The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value on non-recurring basis as of December 31, 2022: Level 1 Level 2 Level 3 Total Asset: Marketable securities held in Trust Account $ 23,632,158 $ — $ — $ 23,632,158 Total Asset $ 23,632,158 $ — $ — $ 23,632,158 Liability: Warrant Liability $ — $ — $ 16,375 $ 16,375 Total Liability $ — $ — $ 16,375 $ 16,375 The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value on non-recurring basis as of December 31, 2021: Level 1 Level 2 Level 3 Total Asset: Marketable securities held in Trust Account $ 58,078,580 $ — $ — $ 58,078,580 Total Asset $ 58,078,580 $ — $ — $ 58,078,580 Liability: Warrant Liability $ — $ — $ 52,151 $ 52,151 Total Liability $ — $ — $ 52,151 $ 52,151 The estimated fair value of the warrants is determined using Level 3 inputs. Inherent in a Monte-Carlo simulation model are assumptions related to expected stock-price volatility (pre-merger and post-merger), expected term, dividend yield and risk-free interest rate. The Company estimates the volatility of its ordinary shares based on management’s understanding of the volatility associated with instruments of other similar entities. The risk-free interest rate is based on the U.S. Treasury Constant Maturity similar to the expected remaining life of the warrants. The expected life of the warrants is simulated based on management assumptions regarding the timing and likelihood of completing a Business Combination. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero. Once the warrants become exercisable, the Company may redeem the outstanding warrants when the price per Class A ordinary shares equals or exceeds $18.00. The assumptions used in calculating the estimated fair values at the end of the reporting period represent the Company’s best estimate. However, inherent uncertainties are involved. If factors or assumptions change, the estimated fair values could be materially different. The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at December 31, 2022 and 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: April 12, December 31, December 31, Inputs 2021 2021 2022 Exercise price $ 11.50 $ 11.50 $ 11.50 Stock price $ 8.07 $ 9.99 $ 7.60 Volatility 24.4 % 7.1 % 38.9 % Expected term of the warrants 5.69 5.35 0.53 Risk-free rate 1.03 1.29 % 4.76 % Dividend yield — — — The following table sets forth a summary of the changes in the fair value of the warrant liability for year ended December 31, 2022: Warrant Liability Fair value as of December 31, 2021 $ 52,151 Change in fair value of warrant liability (35,776 ) Fair value as of December 31, 2022 $ 16,375 The following table sets forth a summary of the changes in the fair value of the warrant liability for the period from January 8, 2021 (inception) to December 31, 2021: Warrant Liability Fair value as of January 8, 2021 (inception) $ — Initial fair value of warrant liability upon issuance at IPO 126,435 Initial fair value of warrant liability upon the exercise of over-allotment option 10,536 Change in fair value of warrant liability (84,820 ) Fair value as of December 31, 2021 $ 52,151

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 — Related Party Transactions Founder Shares On January 13, 2021, the Company issued 1,437,500 founder shares for an aggregate purchase price of $25,001. Up to 187,500 founder shares are subject to forfeiture by the Sponsor depending on the extent to which the underwriters’ over-allotment option is exercised. On April 15, 2021, the underwriter exercised the full overallotment option and therefore the 187,500 founder shares are no longer subject to forfeiture (See Note 8). The Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed (A) to waive their redemption rights with respect to their founder shares and public shares in connection with the completion of the initial Business Combination and (B) to waive their rights to liquidating distributions from the Trust Account with respect to their founder shares if the Company fails to complete the initial Business Combination within the Combination Period, although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete the initial Business Combination within such time period and (iv) the founder shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, as described in the amended and restated memorandum and articles of association. If the Company submits the initial Business Combination to the MPAC public shareholders for a vote, the Sponsor, officers and directors have agreed (and their permitted transferees will agree) to vote their founder shares and any public shares purchased during or after the IPO in favor of the initial Business Combination. Promissory Note - Related Party On January 13, 2021, the Sponsor agreed to loan the Company up to $200,000 to be used for a portion of the expenses of the IPO. These loans are non-interest bearing, unsecured and are due at the closing of the IPO. The Company had borrowed $200,000 under the promissory note and fully repaid as of August 24, 2021. As of December 31, 2022 and 2021, the Promissory Note was terminated. Working Capital Loans In addition, in order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,150,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination company at a price of $10.00 per unit at the option of the lender. Such units would be identical to the Private Placement Units. As of December 31, 2022 and 2021, the Company had no borrowings under the Working Capital Loans. Administrative Support Agreement Commencing on the date of the IPO, the Company will pay the Sponsor $10,000 per month for office space, secretarial and administrative services provided to members of the Company’s management team. Upon completion of the initial Business Combination on January 4, 2023, the Company ceased paying these monthly fees. For the year ended December 31, 2022, the Company incurred $120,000 in expenses in connection with such services. For the period from April 7, 2021 (“Effective Date”) through December 31, 2021, the Company incurred $86,333 in expenses in connection with such services.

Promissory Note _ Legacy MMV

Promissory Note – Legacy MMV	12 Months Ended
	Dec. 31, 2022
Promissory Note [Abstract]
Promissory Note – Legacy MMV	Note 7 — Promissory Note – Legacy MMV On January 6, 2022, each of the parties to the Merger Agreement and Avatar Group Holdings Limited entered into a First Amendment to the Merger Agreement (the “Amendment”). Under the Amendment, Legacy MMV agrees to make to Company, and the Company agrees to borrow from Legacy MMV three tranches of non-interest bearing loans in the aggregate principal amount of $2,750,000, all of which shall become repayable upon closing of the Business Combination, or if the Company, PubCo and Merger Sub materially breach the Merger Agreement or the Amendment and such breach has not been cured within fifteen (15) days after the Company’s receipt of such notice containing the details of breach. As of December 31, 2022, we received $2,684,975 under such loan. On September 29, 2022, the Company, Legacy MMV and other named parties entered into the Second Amendment to the Merger Agreement pursuant to which, Legacy MMV agreed to make an interest-free loan to the Company for an aggregate principal amount of $525,000 in two tranches, all of which shall become repayable only at the closing of a business combination by the Company or as otherwise stipulated. On January 10, 2022, March 21, 2022, June 21, 2022, June 29, 2022 and September 30, 2022, the Company received loans for an aggregate of $2,684,975, from the target company, Legacy MMV. As of December 31, 2022, $2,684,975 was outstanding under this loan.

Commitments & Contingencies

Commitments & Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments & Contingencies	Note 8 — Commitments & Contingencies Registration Rights The holders of founder shares, Private Placement Units, shares being issued to the underwriters of the IPO, and units that may be issued on conversion of Working Capital Loans (and in each case holders of their component securities, as applicable) will be entitled to registration rights pursuant to a registration rights agreement signed prior to or on the effective date of the IPO requiring the Company to register such securities for resale (in the case of the founder shares, only after conversion to the Company’s Class A ordinary shares). The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. Underwriting Agreement The Company granted the underwriter a 45-day option from April 12, 2021 to purchase up to 750,000 additional Units to cover over-allotments, if any, at the IPO price less the underwriting fees and commissions. On April 15, 2021, the underwriter fully exercised the over-allotment option. On April 12, 2021, the Company paid a fixed underwriting fee of $1,000,000. On April 15, an additional of $150,000 underwriting fee was paid as a result of the fully exercise of over-allotment option. Additionally, a deferred underwriting fee of $2,012,500, will be payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes an initial Business Combination, subject to the terms of the underwriting agreement. Upon the consummation of the Business Combination with Legacy MMV, the Company paid part of the deferred underwriting fee of $ 2,0212,500 Representative’s Ordinary Shares The Company has issued to Maxim Partners LLC and/or its designees, 57,500 ordinary shares upon the consummation of IPO and the exercise of the over-allotment option, the fair value of which is $461,968 using the Monte-Carlo simulation model. The fair value of the representative’s ordinary shares granted to Maxim was estimated as of the date of grant using the following assumptions: (1) expected volatility of 14%, (2) risk-free interest rate of 0.05% and (3) fair value per ordinary share of $8.69. The value of the Representative Shares had been recorded as deferred offering costs and additional paid-in capital upon Underwriter’s completion of the IPO services for which it received the Representative Shares as compensation. The deferred offering costs were included in the total offering costs that were allocated among public ordinary shares and warrants upon IPO. Maxim has agreed not to transfer, assign or sell any such shares until the completion of the initial Business Combination. In addition, Maxim has agreed (i) to waive its redemption rights with respect to such shares in connection with the completion of the initial Business Combination and (ii) to waive its rights to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete the initial Business Combination within the Combination Period. The shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the date of the effectiveness of the registration statement pursuant to FINRA Rule 5110(e)(1). Pursuant to FINRA Rule 5110(e)(1), these securities will not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately following the effective date of the registration statement, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the commencement of sales in the IPO, except to any underwriter and selected dealer participating in the offering and their officers, partners, registered persons or affiliates. Right of First Refusal For a period beginning on the closing of the IPO and ending 12 months from the closing of a Business Combination, the Company has granted Maxim a right of first refusal to act as lead-left book running manager and lead left placement agent for any and all future private or public equity, equity-linked, convertible and debt offerings during such period. In accordance with FINRA Rule 5110(g)(6)(A), such right of first refusal shall not have a duration of more than three years from the commencement of sales in the IPO. Subscription Agreement On November 3, 2022, the Company, PubCo and Prominence entered into Prominence Agreement, pursuant to which Prominence has committed to purchase an aggregate of 1,200,000 Class A Ordinary Shares from PubCo at a price per share of $10.00, for gross proceeds of $12,000,000 (the “PIPE Investment”). The closing of the PIPE Investment is conditioned upon, among other things, the completed or concurrent consummation of the Business Combination set forth in the Merger Agreement dated August 6, 2021, as amended on January 6, 2022 and September 29, 2022 by and among the Company, PubCo, Merger Sub, Legacy MMV, and certain shareholders of Legacy MMV. As of December 31, 2022, the Company received $2 million of the PIPE financing. On January 6, 2023, MMV completed the first installment of the PIPE Investment in the amount of US$2 million for the subscription of 200,000 Class A ordinary shares of Pubco to Digital Analog Integration Ltd. (“DAL”), an assignee of Prominence. On January 30, 2023, MMV closed the second installment of the PIPE Investment in the amount of US$2.5 million for the subscription of 250,000 Class A ordinary shares of Pubco to DAL. After a series of negotiations, MMV and Prominence agreed to waive their remaining rights and obligations under the Prominence Agreement.

Shareholders_ Deficit

Shareholders’ Deficit	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Shareholders’ Deficit	Note 9 — Shareholders’ Deficit Preference Shares — no no Class A Ordinary Shares no Class B Ordinary Shares — no Warrants — In addition, if (x) the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s initial shareholders or their affiliates, without taking into account any founder shares held by such shareholders or their affiliates, as applicable, prior to such issuance (the “Newly Issued Price”)), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for funding the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price shall be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described in the section “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. The warrants will become exercisable on the later of 12 months from the closing of the IPO and 30 days after the completion of its initial Business Combination and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of the initial Business Combination, the Company will use best efforts to file, and within 60 business days following the initial Business Combination to have declared effective, a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. No warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such Class A ordinary shares. Notwithstanding the foregoing, if a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective within a specified period following the consummation of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. Once the public warrants become exercisable, the Company may redeem the public warrants: ● in whole and not in part; ● at a price of $0.01 per public warrant; ● upon not less than 30 days ‘prior written notice of redemption to each warrant holder and ● if, and only if, the reported last sale price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted). The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class A ordinary shares may fall below the $18.00 redemption trigger price as well as the $11.50 warrant exercise price after the redemption notice is issued. If the Company calls the warrants for redemption as described above, the management will have the option to require any holder that wishes to exercise his, her or its warrant to do so on a “cashless basis.” In determining whether to require all holders to exercise their warrants on a “cashless basis,” the management will consider, among other factors, the Company’s cash position, the number of warrants that are outstanding and the dilutive effect on the Company’s shareholders of issuing the maximum number of Class A ordinary shares issuable upon the exercise of the warrants. If the management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants for that number of Class A ordinary shares equal to the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) over the exercise price of the warrants by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the Class A ordinary shares for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. If the management takes advantage of this option, the notice of redemption will contain the information necessary to calculate the number of Class A ordinary shares to be received upon exercise of the warrants, including the “fair market value” in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption. The Company believes this feature is an attractive option to the Company if it does not need the cash from the exercise of the warrants after the initial Business Combination. If the Company calls the warrants for redemption and the management does not take advantage of this option, the Sponsor and its permitted transferees would still be entitled to exercise their private placement warrants for cash or on a cashless basis using the same formula described above that other warrant holders would have been required to use had all warrant holders been required to exercise their warrants on a cashless basis. If the number of issued and outstanding Class A ordinary shares is increased by a capitalization payable in Class A ordinary shares, or by a sub-division of Class A ordinary shares or other similar event, then, on the effective date of such capitalization, sub-division or similar event, the number of Class A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the issued and outstanding Class A ordinary shares. A rights offering to holders of Class A ordinary shares entitling holders to purchase Class A ordinary shares at a price less than the fair market value will be deemed a capitalization of a number of Class A ordinary shares equal to the product of (i) the number of Class A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A ordinary shares) multiplied by (ii) one (1) minus the quotient of (x) the price per Class A ordinary share paid in such rights offering divided by (y) the fair market value. For these purposes (i) if the rights offering is for securities convertible into or exercisable for Class A ordinary shares, in determining the price payable for Class A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) fair market value means the volume weighted average price of Class A ordinary shares as reported during the ten (10) trading day period ending on the trading day prior to the first date on which the Class A ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. Rights Each holder of a right will receive one-tenth (1/10) of one Class A ordinary share upon consummation of the initial Business Combination, even if the holder of such right redeemed all Class A ordinary shares held by the holder in connection with the initial Business Combination. No additional consideration will be required to be paid by a holder of rights in order to receive its additional shares upon consummation of an initial Business Combination, as the consideration related thereto has been included in the unit purchase price paid for by investors in the IPO. If the Company enters into a definitive agreement for a Business Combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the Class A ordinary shares will receive in the transaction on an as-converted into Class A ordinary share basis, and each holder of a right will be required to affirmatively convert its rights in order to receive the 1/10 share underlying each right (without paying any additional consideration) upon consummation of the Business Combination. More specifically, the right holder will be required to indicate its election to convert the rights into underlying shares as well as to return the original rights certificates to the Company. If the Company is unable to complete an initial Business Combination within the required time period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the rights will expire worthless. As soon as practicable upon the consummation of the initial Business Combination, the Company will direct registered holders of the rights to return their rights to the rights agent. Upon receipt of the rights, the rights agent will issue to the registered holder of such rights the number of full Class A ordinary shares to which it is entitled. The Company will notify registered holders of the rights to deliver their rights to the rights agent promptly upon consummation of such Business Combination and have been informed by the rights agent that the process of exchanging their rights for Class A ordinary shares should take no more than a matter of days. The foregoing exchange of rights is solely ministerial in nature and is not intended to provide the Company with any means of avoiding the Company’s obligation to issue the shares underlying the rights upon consummation of the initial Business Combination. Other than confirming that the rights delivered by a registered holder are valid, the Company will have no ability to avoid delivery of the shares underlying the rights. Nevertheless, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of an initial Business Combination. The shares issuable upon conversion of the rights will be freely tradable (except to the extent held by affiliates of the Company’s). The Company will not issue fractional shares upon conversion of the rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of British Virgin Island’s law. As a result, you must hold rights in multiples of 10 in order to receive shares for all of the investors’ rights upon closing of a Business Combination. If the Company is unable to complete an initial Business Combination within the required time period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of an initial Business Combination. Accordingly, the rights may expire worthless.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 10 — Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Other than described below, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements. On January 4, 2023, the Company consummated the Business Combination with Legacy MMV. Immediately prior to the consummation of the Business Combination, all outstanding Units of the Company separated into their individual components of the Company’s Class A ordinary shares, public warrants and rights ceased separate existence and trading. Upon the consummation of the Business Combination, the Company’s Class B ordinary shares automatically converted into its Class A ordinary shares, and the current equity holdings of the Company’s shareholders were exchanged as follows: ● Each Class A ordinary share issued and outstanding immediately prior to the effective time of the Reincorporation Merger (other than any redeemed shares) was automatically cancelled and ceased to exist and, for each Class A ordinary share, MMV issued to each of the Company’s shareholder (other than the shareholders who exercised their redemption rights in connection with the Business Combination or the Charter Amendment Proposal) one validly issued MMV Class A ordinary share; ● Each whole warrants issued and outstanding immediately prior to effective time of the Reincorporation Merger was converted into a warrant to purchase one MMV Class A ordinary share (each, a “MMV Warrant”) (or equivalent portion thereof). The MMV Warrants will have substantially the same terms and conditions as set forth in the Company’s warrants; and ● The holders of Rights issued and outstanding immediately prior to the effective time of the Reincorporation Merger received one-tenth (1/10) of one MMV Class A ordinary share in exchange for the cancellation of each Right; provided, however, that each holder entitled to receive a fraction of a MMV Class A ordinary share shall receive, in lieu of such fractional share, one PubCo Class A ordinary share rounding up to the nearest whole MMV Class A ordinary share. On January 6, 2023, MMV completed the first installment of the PIPE Investment in the amount of US$2 million for the subscription of 200,000 Class A ordinary shares of Pubco to Digital Analog Integration Ltd. (“DAL”), an assignee of Prominence. On January 30, 2023, MMV closed the second installment of the PIPE Investment in the amount of US$2.5 million for the subscription of 250,000 Class A ordinary shares of Pubco to DAL. After a series of negotiations, MMV and Prominence agreed to waive their remaining rights and obligations under the Prominence Agreement.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements are presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, ( the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, Section 102(b)(1) of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of these financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents As of December 31, 2022 and 2021, the Company had $2,222,795 and $336,852 in cash. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash and cash equivalents. The Company did not have any cash equivalents as of December 31, 2022 and 2021.
Marketable Securities Held in Trust Account	Marketable Securities Held in Trust Account At December 31, 2022 the assets held in the Trust Account were released to a Trust Operating Account, which was subsequently distributed on and after the Business Combination consummated on January 4, 2023. At December 31, 2021 the assets held in the Trust Account were held in institutional money market mutual funds and cash. The Company’s investments held in the Trust Account are classified as trading securities.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit. As of December 31, 2022 and 2021, the Company has not experienced losses on these accounts.
Class A Ordinary Shares Subject to Possible Redemption	Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, on December 31, 2022 and 2021, 2,241,006 and 5,750,000 shares of Class A ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders’ deficit section of the Company’s balance sheets. All of the 5,750,000 Class A ordinary share sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary share subject to redemption to be classified outside of permanent equity. The Class A ordinary share is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary share resulted in charges against additional paid-in capital and accumulated deficit. As of December 31, 2022 and 2021, the amount for Class A ordinary shares subject to possible redemption reflected in the balance sheets are reconciled in the following table: December 31, December 31, 2022 2021 Gross proceeds from IPO $ 57,500,000 $ 57,500,000 Less: Proceeds allocated to Warrants (136,971 ) (136,971 ) Ordinary share issuance costs (4,120,737 ) (4,120,737 ) Plus: Accretion of carrying value to redemption value 4,257,708 4,257,708 Additional amount deposited into trust 1,949,101 575,000 Remeasurement of Class A ordinary shares subject to possible redemption 526,252 3,580 Less: Class A ordinary shares redeemed on September 29, 2022 (36,343,195 ) — Contingently redeemable ordinary shares $ 23,632,158 $ 58,078,580 On March 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from April 12, 2022 to July 12, 2022. On June 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from July 12, 2022 to October 12, 2022. On September 29, 2022, $36,343,195 was paid from the Trust Account to MPAC public shareholders for redemption of 3,508,994 Class A ordinary shares, and $224,101 was deposited into the trust account by the Company, to extend the Combination Period from October 12, 2022 to January 12, 2023.
Offering Costs	Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A – “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the IPO and were charged to shareholders’ deficit upon the completion of the IPO, while the offering costs attributable to private placement warrants are immaterial and not recorded. Accordingly, as of December 31, 2022, offering costs in the aggregate of $4,120,737 have been charged to shareholders’ deficit (consisting of $1,150,000 of underwriting fee, $2,012,500 of deferred underwriting fee, and $496,269 of other offering costs, and $461,968 of fair value of 57,500 representative’s ordinary shares).
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature.
Income Taxes	Income Taxes ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the British Virgin Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the British Virgin Islands. In accordance with British Virgin Islands federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Warrant Liability	Warrant Liability The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. Derivative instruments are recorded at fair value on the grant date and re- valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. Financial Accounting Standards Board (“FASB”) ASC 470-20, Debt with Conversion and Other Options addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate IPO proceeds from the Units between Class A ordinary shares and warrants, using the residual method by allocating IPO proceeds first to fair value of the warrants and then the Class A ordinary shares. The Company accounts for the private placement warrants as warrant liabilities due to certain features contained in the warrant agreements that give rise to liability treatment. The public warrants are treated as equity as they do not meet the definition of a warrant liability.
Net Loss Per Share	Net Loss Per Share The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 3,021,250 potential common shares for outstanding warrants to purchase the Company’s stock were excluded from diluted earnings per share for the year ended December 31, 2022 and for the period from January 8, 2021 (inception) through December 31, 2021, because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net loss per share for each class of ordinary shares: For the Period from For the Year Ended January 8, 2021 (Inception) to December 31, 2022 December 31, 2021 Class B and Class B and Redeemable Non-redeemable Redeemable Non-redeemable Class A Class B Class A Class B Numerator: Allocation of net loss (1,645,607 ) (608,167 ) (624,726 ) (247,392 ) Denominator: Weighted-average shares outstanding 4,836,700 1,787,500 4,229,692 1,674,958 Basic and diluted net loss per share (0.34 ) (0.34 ) (0.15 ) (0.15 )
Recent Accounting Standards	Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 for the Company and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of ordinary shares subject to possible redemption reflected on the balance sheet	December 31, December 31, 2022 2021 Gross proceeds from IPO $ 57,500,000 $ 57,500,000 Less: Proceeds allocated to Warrants (136,971 ) (136,971 ) Ordinary share issuance costs (4,120,737 ) (4,120,737 ) Plus: Accretion of carrying value to redemption value 4,257,708 4,257,708 Additional amount deposited into trust 1,949,101 575,000 Remeasurement of Class A ordinary shares subject to possible redemption 526,252 3,580 Less: Class A ordinary shares redeemed on September 29, 2022 (36,343,195 ) — Contingently redeemable ordinary shares $ 23,632,158 $ 58,078,580
Schedule of basic and diluted net loss per share for each class of ordinary shares	For the Period from For the Year Ended January 8, 2021 (Inception) to December 31, 2022 December 31, 2021 Class B and Class B and Redeemable Non-redeemable Redeemable Non-redeemable Class A Class B Class A Class B Numerator: Allocation of net loss (1,645,607 ) (608,167 ) (624,726 ) (247,392 ) Denominator: Weighted-average shares outstanding 4,836,700 1,787,500 4,229,692 1,674,958 Basic and diluted net loss per share (0.34 ) (0.34 ) (0.15 ) (0.15 )

Fair Value of Warrant Liabili_2

Fair Value of Warrant Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value of Warrant Liabilities [Abstract]
Schedule of the fair value hierarchy for those assets and liabilities measured	Level 1 Level 2 Level 3 Total Asset: Marketable securities held in Trust Account $ 23,632,158 $ — $ — $ 23,632,158 Total Asset $ 23,632,158 $ — $ — $ 23,632,158 Liability: Warrant Liability $ — $ — $ 16,375 $ 16,375 Total Liability $ — $ — $ 16,375 $ 16,375 Level 1 Level 2 Level 3 Total Asset: Marketable securities held in Trust Account $ 58,078,580 $ — $ — $ 58,078,580 Total Asset $ 58,078,580 $ — $ — $ 58,078,580 Liability: Warrant Liability $ — $ — $ 52,151 $ 52,151 Total Liability $ — $ — $ 52,151 $ 52,151
Schedule of valuation inputs fair value	April 12, December 31, December 31, Inputs 2021 2021 2022 Exercise price $ 11.50 $ 11.50 $ 11.50 Stock price $ 8.07 $ 9.99 $ 7.60 Volatility 24.4 % 7.1 % 38.9 % Expected term of the warrants 5.69 5.35 0.53 Risk-free rate 1.03 1.29 % 4.76 % Dividend yield — — —
Schedule of the fair value of the warrant liability	Warrant Liability Fair value as of December 31, 2021 $ 52,151 Change in fair value of warrant liability (35,776 ) Fair value as of December 31, 2022 $ 16,375 Warrant Liability Fair value as of January 8, 2021 (inception) $ — Initial fair value of warrant liability upon issuance at IPO 126,435 Initial fair value of warrant liability upon the exercise of over-allotment option 10,536 Change in fair value of warrant liability (84,820 ) Fair value as of December 31, 2021 $ 52,151

Organization, Business Operat_2

Organization, Business Operation, Liquidation and Business Combination (Details) - USD ($)						12 Months Ended
	Sep. 29, 2022	Jun. 29, 2022	Mar. 29, 2022	Apr. 15, 2021	Apr. 12, 2021	Dec. 31, 2022	Jan. 30, 2023	Nov. 03, 2022	Sep. 30, 2022	Jun. 21, 2022	Mar. 21, 2022	Jan. 10, 2022
Organization, Business Operation, Liquidation and Business Combination (Details) [Line Items]
Deferred underwriting fee						$ 2,012,500
Other offering costs						$ 496,269
Investments maximum maturity term						180 days
Trust account	$ 1,374,101	$ 1,374,101	$ 1,374,101
Aggregate consideration	$ 300,000,000
Share Price (in Dollars per share)								$ 10
PIPE financing						$ 2,000,000
Cash						2,222,795
Working capital						$ 4,418,109
Loans receivable		$ 2,684,975							$ 2,684,975	$ 2,684,975	$ 2,684,975	$ 2,684,975
IPO [Member]
Organization, Business Operation, Liquidation and Business Combination (Details) [Line Items]
Additional units (in Shares)					5,000,000
Price per share (in Dollars per share)					$ 10
Gross proceeds					$ 50,000,000
Private Placement [Member]
Organization, Business Operation, Liquidation and Business Combination (Details) [Line Items]
Additional units (in Shares)				22,500	270,000
Price per share (in Dollars per share)					$ 10
Gross proceeds				$ 225,000
Over-Allotment Option [Member]
Organization, Business Operation, Liquidation and Business Combination (Details) [Line Items]
Additional units (in Shares)				750,000
Price per share (in Dollars per share)						$ 10.1
Gross proceeds				$ 7,500,000
Amount of transaction costs						$ 4,120,737
Underwriting fee						1,150,000
Deferred underwriting fee				$ 2,012,500		2,012,500
Other offering costs						496,269
Amount of fair value						$ 461,968
Ordinary shares (in Shares)						57,500
Total amount deposited into trust account						$ 58,075,000
Sponsor [Member]
Organization, Business Operation, Liquidation and Business Combination (Details) [Line Items]
Gross proceeds						200,000
Class A Ordinary Shares [Member]
Organization, Business Operation, Liquidation and Business Combination (Details) [Line Items]
Additional interest to public shareholders (in Dollars per share)	$ 0.3	$ 0.3	$ 0.3
Trust account paid	$ 36,343,195
Ordinary shares (in Shares)	3,508,994
Aggregate shares (in Shares)								1,200,000
Aggregate purchase price								$ 12,000,000
Share Price (in Dollars per share)		$ 0.1	$ 0.1
MMV Ordinary Shares [Member]
Organization, Business Operation, Liquidation and Business Combination (Details) [Line Items]
Price per share (in Dollars per share)	$ 10
Ordinary shares (in Shares)	30,000,000
Subsequent Event [Member]
Organization, Business Operation, Liquidation and Business Combination (Details) [Line Items]
PIPE financing							$ 2,500,000
Subsequent Event [Member] | Class A Ordinary Shares [Member]
Organization, Business Operation, Liquidation and Business Combination (Details) [Line Items]
Ordinary shares (in Shares)							250,000
PIPE Investment [Member]
Organization, Business Operation, Liquidation and Business Combination (Details) [Line Items]
PIPE financing						$ 2,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)				12 Months Ended
	Sep. 29, 2022	Jun. 29, 2022	Mar. 29, 2022	Dec. 31, 2022	Dec. 31, 2021	Nov. 03, 2022
Summary of Significant Accounting Policies (Details) [Line Items]
Cash				$ 2,222,795	$ 336,852
Share Price (in Dollars per share)						$ 10
Offering costs				4,120,737
Underwriting fee				1,150,000
Deferred underwriting fee				2,012,500
Other offering costs				$ 496,269
Number of common shares for outstanding warrants to purchase the stock excluded from diluted earnings per share (in Shares)				3,021,250	3,021,250
Class A Ordinary Shares [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Ordinary shares subject to possible redemption (in Shares)				2,241,006	5,750,000
Deposited into the trust account	$ 224,101	$ 575,000	$ 575,000
Share Price (in Dollars per share)		$ 0.1	$ 0.1
Paid from the trust to redeeming shareholders	$ 36,343,195
Shares redeemed (in Shares)	3,508,994
Class A Ordinary Shares [Member] | IPO [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Ordinary shares subject to possible redemption (in Shares)				5,750,000
Representative Ordinary Shares [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Amount of fair value				$ 461,968
Ordinary shares (in Shares)				57,500

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares subject to possible redemption reflected on the balance sheet - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Class A Ordinary Shares Subject To Possible Redemption Reflected On The Balance Sheet [Abstract]
Gross proceeds from IPO	$ 57,500,000	$ 57,500,000
Less:
Proceeds allocated to Warrants	(136,971)	(136,971)
Ordinary share issuance costs	(4,120,737)	(4,120,737)
Plus:
Accretion of carrying value to redemption value	4,257,708	4,257,708
Additional amount deposited into trust	1,949,101	575,000
Remeasurement of Class A ordinary shares subject to possible redemption	526,252	3,580
Less:
Class A ordinary shares redeemed on September 29, 2022	(36,343,195)
Contingently redeemable ordinary shares	$ 23,632,158	$ 58,078,580

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net loss per share for each class of ordinary shares - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Redeemable Class A [Member]
Numerator:
Allocation of net loss	$ (1,645,607)	$ (624,726)
Denominator:
Weighted-average shares outstanding	4,836,700	4,229,692
Basic net loss per share	$ (0.34)	$ (0.15)
Class B and Non-redeemable Class B [Member]
Numerator:
Allocation of net loss	$ (608,167)	$ (247,392)
Denominator:
Weighted-average shares outstanding	1,787,500	1,674,958
Basic net loss per share	$ (0.34)	$ (0.15)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net loss per share for each class of ordinary shares (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Redeemable Class A [Member]
Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net loss per share for each class of ordinary shares (Parentheticals) [Line Items]
Weighted-average shares outstanding diluted	4,836,700	4,229,692
Diluted net loss per share	$ (0.34)	$ (0.15)
Class B and Non-redeemable Class B [Member]
Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net loss per share for each class of ordinary shares (Parentheticals) [Line Items]
Weighted-average shares outstanding diluted	1,787,500	1,674,958
Diluted net loss per share	$ (0.34)	$ (0.15)

Initial Public Offering (Detail

Initial Public Offering (Details) - USD ($)		12 Months Ended
	Apr. 15, 2021	Dec. 31, 2022
IPO [Member]
Initial Public Offering (Details) [Line Items]
Sold units		5,000,000
Price per unit		$ 10
Over-Allotment Option [Member]
Initial Public Offering (Details) [Line Items]
Underwriter option	750,000
Gross proceeds	$ 7,500,000
Class A Ordinary Shares [Member]
Initial Public Offering (Details) [Line Items]
Exercise price of warrants		$ 11.5

Private Placement (Details)

Private Placement (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Private Placement [Member]
Private Placement (Details) [Line Items]
Purchased of aggregate shares | shares	270,000
Price per unit | $ / shares	10
Aggregate amount | $	$ 2,700,000
Sponsor [Member] | Over-Allotment Option [Member]
Private Placement (Details) [Line Items]
Purchased of aggregate shares | shares	22,500
Gross proceeds | $	$ 225,000

Fair Value of Warrant Liabili_3

Fair Value of Warrant Liabilities (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares
Class A Ordinary Shares [Member]
Fair Value of Warrant Liabilities (Details) [Line Items]
Ordinary shares equals or exceeds	$ 18

Fair Value of Warrant Liabili_4

Fair Value of Warrant Liabilities (Details) - Schedule of the fair value hierarchy for those assets and liabilities measured - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Asset:
Marketable securities held in Trust Account	$ 23,632,158	$ 58,078,580
Total Asset	23,632,158	58,078,580
Liability:
Warrant Liability	16,375	52,151
Total Liability	16,375	52,151
Fair Value, Inputs, Level 1 [Member]
Asset:
Marketable securities held in Trust Account	23,632,158	58,078,580
Total Asset	23,632,158	58,078,580
Liability:
Warrant Liability
Total Liability
Fair Value, Inputs, Level 2 [Member]
Asset:
Marketable securities held in Trust Account
Total Asset
Liability:
Warrant Liability
Total Liability
Fair Value, Inputs, Level 3 [Member]
Asset:
Marketable securities held in Trust Account
Total Asset
Liability:
Warrant Liability	16,375	52,151
Total Liability	$ 16,375	$ 52,151

Fair Value of Warrant Liabili_5

Fair Value of Warrant Liabilities (Details) - Schedule of valuation inputs fair value - $ / shares	9 Months Ended	12 Months Ended
	Apr. 12, 2021	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Valuation Inputs Fair Value Abstract
Exercise price (in Dollars per share)	$ 11.5	$ 11.5	$ 11.5
Stock price (in Dollars per share)	$ 8.07	$ 7.6	$ 9.99
Volatility	24.40%	38.90%	7.10%
Expected term of the warrants	5 years 8 months 8 days	6 months 10 days	5 years 4 months 6 days
Risk-free rate	1.03%	4.76%	1.29%
Dividend yield

Fair Value of Warrant Liabili_6

Fair Value of Warrant Liabilities (Details) - Schedule of the fair value of the warrant liability - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of The Fair Value Of The Warrant Liability Abstract
Fair value beginning	$ 52,151
Initial fair value of warrant liability upon issuance at IPO		126,435
Initial fair value of warrant liability upon the exercise of over-allotment option		10,536
Change in fair value of warrant liability	(35,776)	(84,820)
Fair value ending	$ 16,375	$ 52,151

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)			9 Months Ended	12 Months Ended
	Apr. 15, 2021	Jan. 13, 2021	Dec. 31, 2021	Dec. 31, 2022	Aug. 24, 2021
Related Party Transaction [Line Items]
Borrowed amount					$ 200,000
Price per share (in Dollars per share)				$ 10
Incurred expenses			$ 86,333	$ 120,000
Warrant [Member]
Related Party Transaction [Line Items]
Working capital loans				$ 1,150,000
Price per share (in Dollars per share)				$ 11.5
Over-Allotment Option [Member]
Related Party Transaction [Line Items]
Subject to forfeiture of shares (in Shares)	187,500
IPO [Member]
Related Party Transaction [Line Items]
Sponsor agreed to loan		$ 200,000
Sponsor [Member]
Related Party Transaction [Line Items]
Office space, secretarial and administrative services of per month				$ 10,000
Founder Shares [Member]
Related Party Transaction [Line Items]
Shares issued (in Shares)		1,437,500
Aggregate purchase price		$ 25,001
Subject to forfeiture of shares (in Shares)		187,500

Promissory Note _ Legacy MMV (D

Promissory Note – Legacy MMV (Details) - USD ($)						12 Months Ended
	Sep. 30, 2022	Jun. 29, 2022	Jun. 21, 2022	Mar. 21, 2022	Jan. 10, 2022	Dec. 31, 2022	Sep. 29, 2022	Jan. 06, 2022	Dec. 31, 2021
Promissory Note [Abstract]
Aggregate principal amount							$ 525,000	$ 2,750,000
Promissory note received						$ 2,684,975
Proceeds from Notes Payable	$ 2,684,975	$ 2,684,975	$ 2,684,975	$ 2,684,975	$ 2,684,975	$ 2,684,975

Commitments & Contingencies (De

Commitments & Contingencies (Details) - USD ($)					1 Months Ended	12 Months Ended
	Jan. 06, 2023	Nov. 03, 2022	Apr. 15, 2021	Apr. 12, 2021	Jan. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Commitments and Contingencies [Line Items]
underwriting fee				$ 1,000,000
Deferred underwriting fee						$ 2,012,500
Expected to pay						Jan. 04, 2023
Ordinary shares (in Shares)						57,500
Fair value						$ 461,968
Expected volatility						14%
Risk free interest rate						0.05%
Fair value per ordinary share (in Dollars per share)						$ 8.69
Amount received						$ 2,000,000
Pipe investment						2,000,000
Over-Allotment Option [Member]
Commitments and Contingencies [Line Items]
Purchase amount				$ 750,000
underwriting fee			$ 150,000
Deferred underwriting fee			$ 2,012,500			2,012,500
Class A Ordinary Shares [Member]
Commitments and Contingencies [Line Items]
Aggregate purchase (in Shares)		1,200,000
Price per share (in Dollars per share)		$ 10
Gross proceeds		$ 12,000,000
Subsequent Event [Member] | Class A Ordinary Shares [Member]
Commitments and Contingencies [Line Items]
Pipe investment	$ 2,000,000				$ 2,500,000
subscription of ordinary shares	$ 200,000				$ 250,000
Business Combination [Member]
Commitments and Contingencies [Line Items]
underwriting fee						$ 20,212,500

Shareholders_ Deficit (Details)

Shareholders’ Deficit (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stockholders' Equity Note [Line Items]
Preference shares, shares authorized	1,000,000	1,000,000
Preference shares, par value (in Dollars per share)
Preference shares, shares issued
Preference shares, shares outstanding
Price per ordinary share (in Dollars per share)	$ 10
Initial business combination, term	5 years
Warrants description	Once the public warrants become exercisable, the Company may redeem the public warrants:    ● in whole and not in part;     ● at a price of $0.01 per public warrant;     ● upon not less than 30 days ‘prior written notice of redemption to each warrant holder and         ● if, and only if, the reported last sale price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted).
Trigger price (in Dollars per share)	$ 18
warrant exercise price (in Dollars per share)	$ 11.5
Warrant [Member]
Stockholders' Equity Note [Line Items]
Purchase shares	1
Price per ordinary share (in Dollars per share)	$ 11.5
Class A Ordinary Shares [Member]
Stockholders' Equity Note [Line Items]
Ordinary shares, share authorized	100,000,000	100,000,000
Ordinary shares, par value (in Dollars per share)
Ordinary shares, share issued	350,000	350,000
Ordinary shares, share outstanding	350,000	350,000
Ordinary shares subject to possible redemption	2,241,006	5,750,000
Class B Ordinary Shares [Member]
Stockholders' Equity Note [Line Items]
Ordinary shares, share authorized	10,000,000	10,000,000
Ordinary shares, par value (in Dollars per share)
Ordinary shares, share issued	1,437,500	1,437,500
Ordinary shares, share outstanding	1,437,500	1,437,500
Business combination [Member]
Stockholders' Equity Note [Line Items]
Business Combination description	the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s initial shareholders or their affiliates, without taking into account any founder shares held by such shareholders or their affiliates, as applicable, prior to such issuance (the “Newly Issued Price”)), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for funding the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price shall be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described in the section “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($) $ in Millions	Jan. 30, 2023	Jan. 06, 2023
Subsequent Event [Line Items]
Investment	$ 2.5
Common Class A [Member]
Subsequent Event [Line Items]
Ordinary Shares	250,000
Common Class A [Member] | PIPE Shares [Member]
Subsequent Event [Line Items]
Investment		$ 2
Ordinary Shares		200,000